For Oncology Professionals
OncoDNA solutions solve problems faced by Oncologists by identifying most relevant treaments and clinical trials
Our aim at OncoDNA is to help oncologists make better use of Comprehensive Genomic Profiling (CGP) providing support in test selection, reimbursement, result interpretation and access to drugs at all stages of the development cycle for the benefit of patients
Clinical solutions designed by clinical oncology experts
Comprehensive pan-cancer biomarker test for solid biopsies based on NGS DNA, RNA, and protein analysis.
- 638 DNA, 22 RNA
- HRD, MSI, TMB, LOH
- Tunr Around Time <2 weeks
- 70 genes
- SNVs, Indels
- Gene translocations, unusual splicing
- TERT promoter
Personalised liquid biopsy test to monitor disease progression and detect reasons for non response.
- 40 genes
- Up to 15 variants previously identified in the tumour
- Minimal Residual Disease
Clinical actionable report
Molecular profiling data simply presented signposting the oncologist to actions that can compliment and improve your patient treatment plans
OncoSHARE (Powered by OncoKDM®)
Integration all data in one comprehensive report
easy-to-read summary supplemented with detailed scientific data if required
treatment recommendations based on scientific and clinical evidence (accesses to full publications in bibliography part)
Analysis details and quality control
Accurate and reliable clinical interpretation of genomic data is essential for labs. OncoKDM provides the necessary views to labs to ensure the quality of sequencing data by enabling them to control key values. However, if labs require a deeper insight into molecular data such as hotspots, they can utilize the advanced Mercury platform.
Watch the videoVariants detection
Our comprehensive variant analysis allows labs to discover all relevant variants detected through sequencing, which are categorized as SNV, INDEL, CNV, AMP. Additionally, we classify each variant based on its biological and therapeutic impact, using the TIER classification system that follows the established ACMG/AMP guidelines ensuring labs receive detailed and accurate information about each variant's potential clinical significance.
Watch the videoGenomic signatures
In addition to identifying individual alterations, the OncoDEEP kit also focuses on complex genomic signatures and rearrangements, such as HRD, MSI, and TM. Our process includes scoring and reporting the expression of these signatures into OncoKDM, enabling labs to access a comprehensive overview of their patients' molecular profile. By incorporating these signatures into the analysis, we provide a more complete picture of the tumor's biology ensuring the best clinical interpretation.
Watch the videoDrugs recommendation
OncoKDM treatment recommendation provides a clear overview of the most effective treatment options based on official guidelines and clinical evidence, ensuring that non-responders are spared from unnecessary toxicities and ineffective therapies. We list each drug with its associated biomarkers and approval details, allowing oncologists to make informed decisions about the best treatment for the patients.
Watch the videoClinical Trials
Easily find worldwide, relevant clinical trials that have reached at least Phase 2, based on your patient's specific condition and molecular profile. With our advanced search capabilities, you can quickly identify clinical trials that are most likely to benefit your patients and provide them with the latest treatment options available.
Watch the videoA comprehensive summary
Our comprehensive reporting includes key findings, simplified pathway analysis, and treatment recommendations based on both molecular and clinical evidence. This allows labs to easily understand the implications of the molecular profiling results and make informed decisions about the best course of treatment for the patients.
Watch the videoFAQ
How to order an analysis?
How to order an analysis?
What is OncoSHARE?
The link between patients, oncologists and OncoDNA.
Consult the report, network and benchmark with oncologists from all over the world!
OncoSHARE is the OncoDNA interactive web interface, accessible to oncologists and patients, for reporting results, matching similar clinical cases, sharing experience on drug efficacy, and finding out which drug can be applied.
OncoSHARE allows oncologists and patients to connect with each other and encourages the sharing of genomic and treatment data, creating a network effect.
If you need any further information, please contact support@oncodna.com
Is there any reimbursement program for these tests?
Major health insurers, including BUPA Global Insurance, have approved reimbursement in the United Kingdom for our most comprehensive theranostic solution, OncoSTRAT&GO.
BUPA Global Insurance has a specific code (7331B) for the reimbursement of our test.
A direct contract is in place between the two companies, so neither the oncologist nor the patient needs to pay for taking advantage of the benefits of cancer precision medicine.
For all other major UK insurance companies, there is a generic code, BC001211. Oncologists can reference this code to any insurer when requesting the test and when the insurer authorises it for a patient, it can then be reimbursed.
Insurance companies in other countries, like Spain, Chile, South Africa or Poland, are also covering totally or partially the cost of our tests.
If you need any further information, please contact support@oncodna.com